

Ruth L Coleman

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/4882637/ruth-l-coleman-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

30
papers

1,635
citations

12
h-index

32
g-index

32
ext. papers

1,988
ext. citations

12.8
avg, IF

4.05
L-index

#	Paper	IF	Citations
30	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. <i>Diabetes Care</i> , 2021 , 44, 2673-2682	14.6	5
29	Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. <i>ESC Heart Failure</i> , 2021 , 8, 2580-2590	3.7	5
28	Increased Risk of Incident Heart Failure and Death Is Associated With Insulin Resistance in People With Newly Diagnosed Type 2 Diabetes: UKPDS 89. <i>Diabetes Care</i> , 2021 , 44, 1877-1884	14.6	7
27	Effects of Intensive Blood Pressure Treatment on Orthostatic Hypotension : A Systematic Review and Individual Participant-based Meta-analysis. <i>Annals of Internal Medicine</i> , 2021 , 174, 58-68	8	15
26	Refeeding risks in patients requiring intravenous nutrition support: Results of a two-centre, prospective, double-blind, randomised controlled trial. <i>Clinical Nutrition ESPEN</i> , 2021 , 41, 143-152	1.3	0
25	Historical HbA Values May Explain the Type 2 Diabetes Legacy Effect: UKPDS 88. <i>Diabetes Care</i> , 2021 ,	14.6	6
24	Effect of Fenofibrate Therapy on Laser Treatment for Diabetic Retinopathy: A Meta-Analysis of Randomized Controlled Trials. <i>Diabetes Care</i> , 2021 ,	14.6	0
23	Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial. <i>Diabetes Research and Clinical Practice</i> , 2020 , 170, 108488	7.4	3
22	Can the cardiovascular risk reductions observed with empagliflozin in the EMPA-REG OUTCOME trial be explained by concomitant changes seen in conventional cardiovascular risk factor levels?. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1151-1156	6.7	6
21	Impact of Acarbose on Incident Diabetes and Regression to Normoglycemia in People With Coronary Heart Disease and Impaired Glucose Tolerance: Insights From the ACE Trial. <i>Diabetes Care</i> , 2020 , 43, 2242-2247	14.6	4
20	Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). <i>Lancet Diabetes and Endocrinology</i> , 2020 , 8, 206-215	18.1	21
19	Abstract MP36: Effects Of Intensive Blood Pressure Treatment On Orthostatic Hypotension: An Individual-level Meta-analysis. <i>Hypertension</i> , 2020 , 76,	8.5	1
18	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. <i>Diabetes Care</i> , 2020 , 43, 2493-2499	14.6	10
17	Long-term glucose variability and risk of nephropathy complication in UKPDS, ACCORD and VADT trials. <i>Diabetologia</i> , 2020 , 63, 2482-2485	10.3	7
16	Meta-analysis of the impact of alpha-glucosidase inhibitors on incident diabetes and cardiovascular outcomes. <i>Cardiovascular Diabetology</i> , 2019 , 18, 135	8.7	6
15	Simulating the impact of targeting lower systolic blood pressure and LDL-cholesterol levels on type 2 diabetes complication rates. <i>Journal of Diabetes and Its Complications</i> , 2019 , 33, 69-74	3.2	1
14	Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 431-437	18.1	258

13	Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 877-886	18.1	164
12	Microvascular outcomes in type 2 diabetes - Authors Ureply. <i>Lancet Diabetes and Endocrinology</i> , 2017 , 5, 580	18.1	
11	Health selection into neighborhoods among patients enrolled in a clinical trial. <i>Preventive Medicine Reports</i> , 2017 , 8, 51-54	2.6	2
10	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. <i>Nature Genetics</i> , 2016 , 48, 1055-1059	36.3	108
9	Prognostic significance of silent myocardial infarction in newly diagnosed type 2 diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS) 79. <i>Circulation</i> , 2013 , 127, 980-7	16.7	76
8	Evaluation of a self-administered oral glucose tolerance test. <i>Diabetes Care</i> , 2013 , 36, 1483-8	14.6	11
7	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. <i>Nature Genetics</i> , 2011 , 43, 117-20	36.3	319
6	Performance of the UK Prospective Diabetes Study Risk Engine and the Framingham Risk Equations in Estimating Cardiovascular Disease in the EPIC- Norfolk Cohort. <i>Diabetes Care</i> , 2009 , 32, 708-13	14.6	108
5	Predicting 6-year mortality risk in patients with type 2 diabetes: response to Wells et al. <i>Diabetes Care</i> , 2009 , 32, e60; author reply e61	14.6	1
4	Framingham, SCORE, and DECODE risk equations do not provide reliable cardiovascular risk estimates in type 2 diabetes. <i>Diabetes Care</i> , 2007 , 30, 1292-3	14.6	137
3	Non-HDL cholesterol is less informative than the total-to-HDL cholesterol ratio in predicting cardiovascular risk in type 2 diabetes. <i>Diabetes Care</i> , 2005 , 28, 1796-7	14.6	41
2	Risk factors for myocardial infarction case fatality and stroke case fatality in type 2 diabetes: UKPDS 66. <i>Diabetes Care</i> , 2004 , 27, 201-7	14.6	220
1	Career story: Medical Statistician. <i>Significance</i> , 2004 , 1, 174-175	0.5	